natgillin/translations-raw huggingface dataset:
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola servar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagaie, and rabies virus.
Cepivo je namenjeno aktivni imunizaciji zdravih pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo virus pasje kuge, pasji parvovirus, pasji adenovirus tipa 1 in 2, virus pasje parainfluence, Leptospira interrogans serološka skupina Australis serovar Bratislava, Leptospira interrogans serološka skupina Canicola serovar Canicola, Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae in virus stekline.
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus Types 1 and 2, and canine parainfluenza virus.
Cepivo je namenjeno aktivni imunizaciji pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo virus pasje kuge, pasji parvovirus, pasji adenovirus tipa 1 in 2 in virus pasje parainfluence.
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagaie.
Cepivo je namenjeno aktivni imunizaciji zdravih pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo virus pasje parainfluence, Leptospira interrogans serološka skupina Australis serovar Bratislava, Leptospira interrogans serološka skupina Canicola serovar Canicola, Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae.
The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa and Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagaie.
Cepivo je namenjeno aktivni imunizaciji zdravih pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo Leptospira interrogans serološka skupina Australis serovar Bratislava, Leptospira interrogans serološka skupina Canicola serovar Canicola, Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa in Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae.
The vaccine is intended for use 5-7 weeks before the birth of the litter (farrowing) with a second vaccination at 2 weeks prior to farrowing.
Cepljenje izvedemo dvakrat, in sicer prvo 5–7 tednov pred rojstvom legla (prasitvijo) ter drugo 2 tedna pred prasitvijo.
The vaccine is made using an ‘adjuvant system’ that contains MPL, a purified lipid (a fat-like substance) extracted from bacteria, which enhances the response of the immune system to the vaccine.
Cepivo se proizvaja ob uporabi sistema adjuvansov, ki vsebuje MPL, tj. prečiščen lipid (snov, podobno maščobam), pridobljen iz bakterij, ki okrepi odziv imunskega sistema na cepivo.
The vaccine is not intended for birds in lay.
Ne uporabite pri pticah v obdobju nesnosti.
The vaccine is presented in boxes of 1 or 10 bottles of 500 ml.
Cepivo je v škatlah z eno ali desetimi plastenkami po 500 ml.
The vaccine is presented in cardboard boxes with 1 or 10 PET vials containing 10, 20, 50, 100, 200, 250 or 500 ml, closed with a rubber stopper and aluminium cap.
Cepivo je pakirano v kartonske škatle z 1 ali 10 vialami iz PET po 10, 20, 50, 100, 200, 250 ali 500 ml, zaprtimi z gumijastimi zamaški in aluminijastimi zaporkami.
The vaccine is reconstituted by adding the contents of the vial containing the DTPa-HBV-IPV suspension by means of a syringe to the vial containing the powder.
Cepivo rekonstituiramo s pomočjo injekcijske brizge, z dodajanjem vsebine viale s supenzijo DTPa- HBV-IPV viali, ki vsebuje prašek.
The vaccine is reconstituted by adding the entire contents of the vial containing the DTPa-HBV-IPV suspension by means of a syringe to the vial containing the powder.
Cepivo rekonstituiramo s pomočjo injekcijske brizge, z dodajanjem celotne vsebine viale s suspenzijo DTPa-HBV-IPV v vialo, ki vsebuje prašek.
The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).
Cepivo je treba injicirati intramuskularno (i.m.) ali subkutano (s.c.).
The vaccine is to stimulate active immunity in broiler breeders in order to provide passive immunity to the progeny against Ornithobacterium rhinotracheale serotype A .
Cepivo uporabljamo za spodbujanje aktivne imunosti pri brojlerskih matičnih jatah, da bi vzbudili pasivno imunost potomcev proti Ornithobacterium rhinotracheale, serotip A.
The vaccine is to stimulate active immunity in broiler breeders in order to provide passive immunity to the progeny against Ornithobacterium rhinotracheale serotype A.
Cepivo uporabljamo za spodbujanje aktivne imunosti pri brojlerskih matičnih jatah, povzroči pasivno imunost potomcev proti Ornithobacterium rhinotracheale, serotip A.
The vaccine is used to prevent viraemia (the presence of the viruses in the blood) in cattle from two and a half months of age.
Cepivo se uporablja za preprečevanje viremije (prisotnosti virusov v krvi) pri govedu, starejšem od dveh mesecev in pol.
The vaccine is used to prevent viraemia (the presence of the viruses in the blood) in sheep from one and a half months of age.
Cepivo se uporablja za preprečevanje viremije (prisotnosti virusov v krvi) pri ovcah, starejših od enega meseca in pol.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) and reduce the signs of the disease.
Cepivo se uporablja za preprečevanje viremije (prisotnosti virusa v krvi) in zmanjšanje znakov bolezni.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) and to reduce clinical signs caused by bluetongue virus in sheep and to prevent viraemia in cattle.
Cepivo se uporablja za preprečevanje viremije (prisotnosti virusov v krvi) in zmanjšanje kliničnih znakov, ki jih povzroča virus bolezni modrikastega jezika, pri ovcah ter za preprečevanje viremije pri govedu.
The vaccine is ‘adsorbed’ on aluminium compounds.
Cepivo je „adsorbirano“ na aluminijeve spojine.
The vaccine is ‘adsorbed’, which means that the virus-like particles and the MPL are fixed onto an aluminium compound, to stimulate a better immune response.
Cepivo je adsorbirano, kar pomeni, da so virusu podobni delci ter MPL vezani na aluminijevo spojino, kar spodbudi boljši imunski odziv.
The vaccine is ‘adsorbed’.
Cepivo je „adsorbirano“.
The vaccine may be administered to individuals of 60 years of age and over, especially in those who run an increased risk of associated complications.
Cepivo se lahko daje odraslim starejšim od 60 let, še zlasti tistim, pri katerih obstaja povečano tveganje za z gripo povezane zaplete.
The vaccine may be applied by an automatic syringe.
Cepivo se lahko injicira z avtomatsko brizgo.
The vaccine may be delivered as a freeze-dried cake in a glass vial or as freeze-dried spheres in cups.
Cepivo je lahko v obliki liofilizirane pogače v stekleni viali ali v obliki liofiliziranih kroglic v mericah.
The vaccine may be used during lactation.
Cepivo se lahko uporablja med dojenjem.
The vaccine may commonly cause transient oedema at the site of injection.
Vnos cepiva lahko pogosto povzroči edem na vbodnem mestu.
The vaccine may not prevent hepatitis B in these individuals.
Pri takšnih bolnikih je mogoče, da cepivo ne prepreči hepatitisa B.
The vaccine may not prevent hepatitis B in these individuals.
V takšnih primerih cepivo ne more preprečiti hepatitisa B.
The vaccine must only be given by injection into a muscle.
Cepivo se sme dajati le z injiciranjem v mišico.
The vaccine response rate was 90.9% (range 80.8% to 94.5%) for varicella based on a post-vaccination antibody titer ≥5 gpELISA units/ml (an antibody titer that has been shown to be highly correlated with long-term protection).
Delež odziva na cepljenje s post- vakcinacijskim titrom protiteles ≥ 5 gpELISA enot/ml (titer protiteles, ki dokazano dobro sovpada z dolgoročno zaščito), je znašal 90,9 % (razpon od 80,8 % do 94,5 %).
The vaccine response was defined as the proportion of subjects with: rSBA titres  32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre < 8) at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥ 8)
Odziv na cepivo je bil opredeljen kot delež oseb s: titri rSBA  32 pri uvodoma seronegativnih preskušancih (tj. titer rSBA pred cepljenjem < 8) vsaj 4-kratnim porastom titrov rSBA od pred cepljenja do po cepljenju pri uvodoma seropozitivnih preskušancih (tj. titer rSBA pred cepljenjem ≥ 8)
The vaccine should be administered in accordance with the recommended posology (see section 3 “How Adjupanrix is given”).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 3 "Kako uporabljati cepivo Adjupanrix").
The vaccine should be administered in accordance with the recommended posology (see section 3 “How Arepanrix is given”).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 3 "Kako uporabljati cepivo Arepanrix").
The vaccine should be administered in accordance with the recommended posology (see section 3 “How Pandemrix is given”).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 3 "Kako uporabljati cepivo Pandemrix").
The vaccine should be administered in accordance with the recommended posology (see section 3 “How Prepandrix is given”).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 3 "Kako uporabljati cepivo Prepandrix").
The vaccine should be administered in accordance with the recommended posology (see section 4.2).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 4.2)
The vaccine should be administered in accordance with the recommended posology (see section 4.2).
Cepivo je treba uporabiti v skladu s priporočenim odmerjanjem (glejte poglavje 4.2).
The vaccine should be allowed to reach room temperature before use.
Cepivo naj pred uporabo doseže sobno temperaturo.
The vaccine should be allowed to reach room temperature before use.
Pred uporabo morate pustiti, da cepivo doseže sobno temperaturo.
The vaccine should be used as supplied.
Cepivo morate uporabiti, kot je pripravljeno.
The vaccine should be used as supplied; no reconstitution is necessary.
Cepivo je treba uporabiti, kot je dobavljeno; rekonstitucija ni potrebna.
The vaccine should be visually inspected both before and after re-suspension for any foreign particulate matter and/or change in physical appearance.
Pred ali po tem, ko se cepivo pretrese, ga je potrebno vizualno pregledati glede morebitne prisotnosti tujih delcev in/ali spremenjenega fizikalnega videza.
The vaccine should be well shaken in order to obtain a homogeneous turbid white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration.
Pred aplikacijo morate cepivo dobro pretresti, da nastane homogena motna bela suspenzija, in ga vizualno preveriti glede morebitne prisotnosti tujih delcev in/ali spremenjenega fizičnega izgleda.
The vaccine should be well shaken to obtain a homogeneous white suspension and be inspected visually for any particulate matter and/or variation of physical aspect prior to administration.
Cepivo morate pred uporabo dobro pretresti, da nastane bela homogena suspenzija, in ga pred aplikacijo dobro pregledati, da ne vsebuje delcev in/ali ni drugačnega fizikalnega videza.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Pred uporabo morate cepivo dobro pretresti, da nastane rahlo motna bela suspenzija in ga vizualno pregledati glede morebitnih tujih delcev in/ali nenormalnega fizikalnega videza.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration.
Pred uporabo morate cepivo dobro pretresti, da nastane rahlo motna bela suspenzija in ga vizualno pregledati glede morebitnih tujih delcev in/ali odstopanja od fizikalnega videza.
The vaccine should be well shaken to obtain a slightly opaque, white suspension and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration.
Pred uporabo morate cepivo dobro pretresti, da nastane rahlo motna, bela suspenzija in ga vizualno pregledati glede morebitnih tujih delcev in/ali odstopanja od fizikalnega videza cepiva.
The vaccine should never be given into a blood vessel or into the skin.
Cepiva se ne sme nikoli dati v žilo ali pod kožo.
The vaccine should never be given into a blood vessel.
Cepivo se ne sme nikoli dati v žilo.
The vaccine should never be given into a blood vessel.
Cepivo se ne sme nikoli injicirati v žilo.
The vaccine should never be given into a vein.
Cepiva nikoli ne smete dobiti v veno.
The vaccine should never be given into a vein.
Cepiva se v nobenem primeru ne sme vbrizgati v veno.
The vaccine should not be used if foreign particles are present in the suspension.
Če so v suspenziji prisotni tujki, cepiva ne smete uporabiti.
The vaccine stimulates active immunity against equine influenza and tetanus.
Cepivo spodbuja aktivno imunost proti konjski influenci.
The vaccine stimulates active immunity against West Nile virus in horses.
Cepivo stimulira aktivno imunost proti virusu West Nile pri konjih.
The vaccine strain can be detected in tissues (liver, heart) until 6 days (chickens) or in tissues (thoracic air sacs) until 4 days (turkeys) post vaccination.
Do 6 dni po cepljenju je možno vakcinalni sev določiti v tkivih pri piščancih (jetra, srce) oziroma do 4 dni v tkivih pri puranih (zračne vrečke).
The vaccine strain can be found in the spleen for at least 35 days.
Cepni sev je lahko v vranici prisoten vsaj 35 dni.
The vaccine strain is a recombinant Herpesvirus of turkeys (HVT) expressing the protective antigen (VP2) of the Infectious Bursal Disease Virus (IBDV) strain Faragher 52/70.
Sev virusa v cepivu je rekombinantni puranji herpesvirus (HVT), ki izraža zaščitne antigene (VP2) virusa infekcioznega burzitisa (IBDV) sev Faragher 52/70.
The vaccine strain is sensitive to penicillins, tetracyclines, macrolides and lincomycin.
Cepni sev je občutljiv za peniciline, tetracikline, makrolide in za linkomicin.
The vaccine strain vCP2017 in Proteq West Nile is a ‘carrier’ canarypox virus that has been given a gene that makes it able to produce part of the West Nile virus, the proteins PreM and E. The canarypox viruses do not spread or multiply in the vaccinated horses.
Sev cepiva vCP2017 v zdravilu Proteq West Nile je „prenašalec“ virusa Canarypox z dodanim genom, ki omogoča tvorjenje dela virusa West Nile, in sicer beljakovin PreM in E. Virusi Canarypox se pri cepljenih konjih ne širijo ali razmnožujejo.
The vaccine strains are able to infect sheep and swine when administered intranasally, but no adverse reactions or spreading to in-contact animals occurred.
Sevi cepiva lahko okužijo ovce in svinje, kadar jih damo intranazalno, vendar niso dokazali neželenih učinkov ali kontaktnega širjenja na živali.
The vaccine strains vCP2242 and vCP3011 are recombinant canarypox viruses expressing the haemagglutinin HA gene from the equine influenza virus strains A/eq/Ohio/03 (American strain, Florida sublineage clade 1) and A/eq/Richmond/1/07 (American strain, Florida sublineage clade2), respectively.
Seva cepiva vCP3011 in vCP2242 sta rekombinantna canarypox virusa, ki izražata hemaglutinin HA gen sevov A/eq/Ohio/03 (ameriški sev, podvrsta Florida 1) in A/eq/Richmond/1/07 (ameriški sev, podvrsta Florida 2) virusa konjske influence.
The vaccine suspension is filled in a volume of 3 ml in bottles (type I glass) with a rubber stopper (bromobutyl rubber) and a screw cap.
Suspenzija za cepljenje je polnjena v 3-mililitrskih steklenicah (steklo tipa I) z gumijastim zamaškom (bromobutilna guma) in pokrovčkom na navoj.
The vaccine suspension should be inspected visually before and after reconstitution for any foreign particule matter and/or abnormal physical appearance.
Preveriti morate videz suspenzije cepiva, pred in po rekonstituciji, glede morebitne prisotnosti tujih delcev in/ali neobičajnega fizikalnega videza cepiva.
The vaccine suspension should be spread evenly over the correct number of chickens, at a distance of 30–40 cm using a coarse spray, preferably when the chickens are sitting together in dim light.
Suspenzijo cepiva je treba z razpršilnikom z večjimi kapljicami enakomerno razpršiti po ustreznem številu piščancev z razdalje 30 do 40 cm, najbolje takrat, ko sedijo in so zbrani na enem mestu ter pri šibkejši svetlobi.
The vaccine suspension should then be mixed with the buffer solution and drunk within 2 hours.
Suspenzijo za cepljenje je treba nato premešati s pufrsko raztopino in spiti v najkasneje 2 urah.
The vaccine targets three strains of influenza virus following the recommendations by the World Health Organisation for the 2015/2016 season.
Cepivo je usmerjeno na tri seve virusa gripe z upoštevanjem priporočil Svetovne zdravstvene organizacije za sezono 2015/2016.
The vaccine virus may spread from vaccinated to non-vaccinated chickens and appropriate care should be taken to separate vaccinated from non-vaccinated.
Cepni virus se lahko razširi s cepljenih na necepljene piščance in paziti je treba, da so cepljeni piščanci ločeni od necepljenih.
The vaccine virus strain CPV-2b has not been tested in domestic cats and other carnivores (except dogs) that are known to be susceptible to canine parvoviruses.
Vakcinalni sev CPV-2b ni bil preizkušen na domačih mačkah ali drugih mesojedih (z izjemo psov), ki so dovzetni za pasje parvoviruse.
The vaccine will be given by gently squeezing the tube and delivering the vaccine into your child’s mouth.
Cepivo bo dal-a tako, da bo iz tube cepivo nežno iztisnil-a v otrokova usta.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.
Cepivo ne prepreči okužbe z drugimi povzročitelji, kot so virusi hepatitisa A, hepatitisa C in hepatitisa E, in z drugimi patogeni, ki okužijo jetra.
The vaccine will not prevent infection caused by other agents such as hepatitis C and hepatitis E and other pathogens known to infect the liver.
Cepivo ne bo preprečilo okužb z drugimi povzročitelji, kot sta virus hepatitisa C in virus hepatitisa E, ter z drugimi patogeni, ki okužijo jetra.
The vaccine works by helping the body to make its own antibodies, which protect your child against these diseases.
Cepivo deluje tako, da pomaga telesu tvoriti lastna protitelesa, ki ščitijo vašega otroka pred naštetimi boleznimi.
The vaccine works by specifically stimulating the body’s natural defense system of the vaccinated person.
Cepivo deluje s specifičnim spodbujanjem naravnega telesnega obrambnega sistema cepljene osebe.
The vaccines contains 5 micrograms thiomersal (see section 4.4).
Cepivo vsebuje 5 mikrogramov tiomersala (glejte poglavje 4.4).
The vaccine’s effectiveness was assessed in one main study involving 2,654 adults, around half of whom were elderly (over 60 years of age).
Učinkovitost cepiva so proučevali v eni glavni študiji z 2 654 bolniki, od katerih jih je bila približno polovica starejših (starejših od 60 let).
The validity of the test result may be affected if the patient is currently being treated with antibiotics or a proton-pump inhibitor or has completed a course of treatment with these medicinal products.
Na zanesljivost testnih rezultatov lahko vpliva, če se bolnik trenutno zdravi z antibiotiki ali zaviralcem protonske črpalke oz. če je pravkar zaključil zdravljenje s tovrstnimi zdravili.
The values tended to stabilize early in the study and did not increase further with continued treatment.
Vrednosti so se stabilizirale v zgodnjem obdobju študije in se med nadaljevanjem zdravljenja niso dodatno zvišale.
The values were lowered by about 8-10 mmHg.
Vrednosti so se znižale za približno 8–10 mmHg.
The vardenafil results showed an increase in QTc (Fridericia) of 8 msec (90% CI: 6-9) and 10 msec (90% CI: 8-11) at 10 and 80 mg doses compared to placebo and an increase in QTci of 4 msec (90% CI: 3-6) and 6 msec (90% CI: 4-7) at 10 and 80 mg doses compared to placebo, at one hour post-dose.
Raziskovalci so ugotovili, da se eno uro po zaužitju 10- ali 80- miligramskega odmerka vardenafila QTc (Fridericia) zveča za 8 msec (90-odstotni interval zaupanja: 6-9) in 10 msec (90-odstotni interval zaupanja: 8-11) v primerjavi s placebom, QTci za 4 msec (90- odstotni interval zaupanja: 3-6) in 6 msec (90-odstotni interval zaupanja: 4-7).
The variety (serotype) of the virus in the vaccine is selected depending on which serotypes are circulating and causing disease at the time of manufacture, so it may contain serotype 1, 4 or 8 or a combination of any two of these.
Vrsta (serotip) virusa v cepivu je izbrana glede na to, kateri serotipi krožijo in povzročajo obolenje v času proizvodnje cepiva, zato lahko vsebuje serotip 1, 4 ali 8 oziroma kombinacijo dveh.
The vast majority (approximately 80%) of patients who presented with a thyroid event after treatment were anti-TPO antibody negative at baseline.
Večina bolnikov (približno 80 %), pri katerih so se po zdravljenju pojavili neželeni dogodki, povezani s ščitnico, je bila na začetku zdravljenja negativna na anti-TPO protitelesa.
The vast majority of patients had adenocarcinoma (92.1%).
Velika večina bolnikov je imela adenokarcinom (92,1 %).
The vast majority of patients had adenocarcinoma (93.3%) and had either never been or were former smokers (96.9%).
Velika večina bolnikov je imela adenokarcinom (93,3 %) in niso nikdar bili kadilci ali pa so bili nekdanji kadilci (96,9 %).
The VEGF receptor can be present at high levels in tumours and helps in the development of new blood vessels that supply the tumours.
Receptor za VEGF je lahko pri raku želodca prisoten v velikih količinah in prispeva k razvoju novih krvnih žil, ki oskrbujejo tumorje.
The veins of the hand dorsum and those close to joints should be avoided.
Če je možno, ne uporabite ven hrbtišča dlani ali ven v bližini sklepov.
The venipuncture set provided with the product must not be used for drawing blood because it contains an in-line filter.
Priloženi pribor za vensko punkcijo se ne sme uporabljati za jemanje krvi, ker vsebuje filter.
The vernakalant dose recommendation is a titrated therapy with two possible dose steps.
Za odmerjanje vernakalanta je priporočljivo titrirano zdravljenje z dvema možnima korakoma odmerjanja.
The very common or common undesirable effects of mifamurtide treatment (such as dizziness, vertigo, fatigue and blurred vision) may have an effect on the ability to drive and use machines.
Nekateri zelo pogosti ali pogosti neželeni učinki mifamurtida (kot so omotica, vrtoglavica, utrujenost in zamegljen vid) lahko vplivajo na sposobnost vožnje in upravljanja s stroji.
The veterinarian should determine the optimum vaccination schedule according to the local situation.
Veterinar določi optimalno shemo cepljenja glede na lokalne razmere.